Does psilocybin work for depression? What the trials actually found

Psilocybin research is the most over-reported and under-read area in psychiatry. The headlines are dramatic, the underlying trials are genuinely interesting, and the gap between the two is where most people's understanding lives.

This page goes trial by trial. For each one: what it found, and the specific problem recorded against it. Every study summary is free to read with no account and carries a trust score calculated from facts about the paper.

This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Psilocybin is not FDA-approved for any condition.

The structural problem: you can tell you took it

Start here, because it affects every trial below.

A placebo-controlled trial depends on participants not knowing which arm they are in. With a psychedelic, they usually know. In the 2022 trial of psilocybin-assisted psychotherapy for alcohol use disorder, the paper's own blinding assessment showed most participants correctly guessed their assignment [6] — and the control was diphenhydramine, a weak psychoactive that does not remotely mimic the experience.

Study summary: Psilocybin-Assisted Psychotherapy vs Placebo in Alcohol Use Disorder — strong evidence, 77/100

This is not a reason to dismiss the field. It is a reason to treat every effect size in it as containing an unknown quantity of expectancy — the participant's belief that something profound is happening — mixed in with whatever the drug does.

The head-to-head trial, and its null result

The trial people cite most is also the one whose result is most often misstated.

In 2021 the New England Journal of Medicine published a trial of psilocybin versus escitalopram, a standard SSRI. Its primary outcome was null [1] — it did not demonstrate that psilocybin outperformed the SSRI on the main measure.

Study summary: Trial of Psilocybin versus Escitalopram for Depression — strong evidence, 78/100

The caveat recorded on it names two things: the investigators are prominent psychedelic-research advocates, and blinding was imperfect in both arms. It also names the media problem directly — the null primary endpoint is routinely glossed over in coverage that leads with secondary outcomes.

If you want the comparator's own evidence base, we have it: escitalopram's approval journey.

The trial with the huge effect size

A 2021 JAMA Psychiatry randomised trial of psilocybin-assisted therapy for major depressive disorder reported a large benefit [2].

Study summary: Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder — strong evidence, 75/100

The caveat is the whole story here: it was waitlist-controlled — no placebo at all — with a very small sample, at a single site with a strong psychedelic-research identity. Effect sizes that large rarely survive larger placebo-controlled replication.

A waitlist control tells you psilocybin-plus-intensive-therapist-contact beats being on a waiting list. That is a much weaker claim than it sounds, because being on a waiting list is not a treatment.

The sponsor-run trials

Two of the most-cited trials were run by organisations seeking approval of the exact product tested.

The 2022 NEJM trial of a single psilocybin dose for treatment-resistant depression was sponsor-run by the company seeking FDA approval, and — the detail that matters most — benefit at week 3 had faded for many participants by week 12, with sustained response a minority outcome in the full paper [3].

Study summary: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression — moderate evidence, 55/100

The 2023 JAMA single-dose trial has a subtler version of the same issue. Its sponsor, Usona, is a 501(c)(3) rather than a commercial company — but it is still the sponsor-developer seeking FDA approval of that product, which is why our rubric scores it as industry funding regardless of tax status [4]. Its result was response without remission for many participants: measurably better, not well.

Study summary: Single-Dose Psilocybin Treatment for Major Depressive Disorder — moderate evidence, 59/100

Non-profit status does not neutralise a structural interest in the outcome. Recording it as industry funding is the conservative call, and we would rather be conservative in public than flattering.

The cancer trial

The 2016 trial in patients with life-threatening cancer reported substantial and sustained decreases in depression and anxiety [5].

Study summary: Psilocybin in patients with life-threatening cancer — strong evidence, 70/100

Its caveat: a crossover design with a discriminable active dose means most participants likely knew their condition, and the Heffter-funded investigators are proponents of the therapy. The blinding problem again, in a different shape.

So what does it add up to?

An honest summary, which is less exciting than either camp wants:

• There is a real and repeated signal. Multiple independent groups find something.
• The signal is measured in trials with a blinding problem the field has not solved, which means the effect attributable to the drug specifically is not well established.
• The one head-to-head against a standard antidepressant was null on its primary outcome.
• Where durability was measured, benefit frequently faded.
• The largest effects come from the least rigorously controlled designs — which is the pattern you would expect if expectancy were doing meaningful work.
• It is not approved. Where regulators actually stand on each psychedelic is tracked separately, on our psychedelic therapy FDA status tracker.

None of that means psilocybin does not work. It means the confident claims in both directions are ahead of the evidence, and the trials that would settle it — large, well-controlled, independently funded, with long follow-up — mostly have not been run yet.

Why this page shows its working

Every study above is linked to a summary you can read free, with its source, its trust score, and the reasoning behind that score. The caveats are not editorial hedging: they are recorded against each study because a specific weakness exists, and they render next to the badge every time, because a gold-standard pill on its own is the half that flatters.

The scoring rubric is public, including the parts that do not flatter us. Browse the evidence library.

If you are in crisis right now, please do not wait: call or text 988 (Suicide & Crisis Lifeline) or text HOME to 741741 (Crisis Text Line). Both are free, confidential and staffed 24/7.